Implantable Neuromodulation and Spinal Cord Stimulation Devices Market Global Report 2026

The implantable neuromodulation and spinal cord stimulation devices market size has grown rapidly in recent years. It will grow from $9.31 billion in 2025 to $10.53 billion in 2026 at a compound annual growth rate (CAGR) of 13.1%. The growth in the historic period can be attributed to growth in chronic pain prevalence worldwide, increasing adoption of spinal cord stimulation for pain management, expansion of neurology treatment infrastructure, rising acceptance of implantable medical devices, early advancements in implantable pulse generator technology.

The implantable neuromodulation and spinal cord stimulation devices market size is expected to see rapid growth in the next few years. It will grow to $16.96 billion in 2030 at a compound annual growth rate (CAGR) of 12.6%. The growth in the forecast period can be attributed to integration of ai-driven adaptive neuromodulation systems, increasing demand for minimally invasive neurological therapies, growth in personalized and precision neurology treatments, rising adoption of wireless implantable medical devices, advancement in closed-loop neurostimulation technologies. Major trends in the forecast period include rising adoption of closed loop adaptive neuromodulation systems for real time pain management optimization, increasing demand for rechargeable implantable pulse generators to reduce surgical replacement procedures, growing use of spinal cord stimulation devices for chronic pain and neuropathic conditions, expansion of wireless and remotely programmable neuromodulation devices for personalized therapy delivery, rising integration of sacral neuromodulation devices for bladder and bowel dysfunction treatments.

The growing incidence of neurological disorders is expected to propel the growth of the implantable neuromodulation and spinal cord stimulation devices market going forward. Neurological disorders are diseases of the nervous system that impair the functioning of the brain, spinal cord, or peripheral nerves, leading to physical, cognitive, or behavioral abnormalities. Neurological disorders are increasing due to the rising prevalence of diabetes, as prolonged high blood sugar levels can damage nerves and blood vessels, increasing the risk of neurological conditions such as neuropathy, stroke, and cognitive impairment. Implantable neuromodulation and spinal cord stimulation devices help manage neurological disorders by delivering controlled electrical impulses to specific nerves or areas of the spinal cord and brain, helping reduce chronic pain, restore nerve signaling, and improve symptoms associated with conditions such as Parkinson’s disease, epilepsy, and spinal cord injuries. For instance, in December 2025, according to the Australian Institute of Health and Welfare, an Australia-based government agency, in 2024, approximately 425,000 Australians were living with dementia (a type of neurological disorder), and this number is projected to increase 2.5 times to over 1.1 million by 2065, including around 662,000 women and 390,000 men. Therefore, the growing incidence of neurological disorders is driving the growth of the implantable neuromodulation and spinal cord stimulation devices market.

The increasing healthcare expenditure is expected to propel the growth of the implantable neuromodulation and spinal cord stimulation devices market going forward. Healthcare expenditure is the total spending by governments, organizations, and individuals on medical services, healthcare products, and activities aimed at maintaining or improving health. Healthcare expenditure is increasing due to advancements in medical technology, as the adoption of innovative diagnostic tools, robotic surgeries, and advanced treatment procedures improves patient care but also raises the overall cost of healthcare services. Increasing healthcare expenditure supports the growth of implantable neuromodulation and spinal cord stimulation devices by enabling greater investment in advanced pain management technologies, improving patient access to implantable therapies, and expanding healthcare infrastructure for specialized neurological treatments. For instance, in April 2025, according to the Office for National Statistics, a UK-based independent producer of official statistics, in 2024, the UK’s healthcare spending reached around $370.71 billion (£317 billion), reflecting a 6.5% nominal increase compared with 2023. Therefore, the increasing healthcare expenditure is driving the growth of the implantable neuromodulation and spinal cord stimulation devices market.

Major companies operating in the implantable neuromodulation and spinal cord stimulation devices market are focusing on developing innovative solutions such as closed-loop, rechargeable spinal cord stimulators to provide personalized pain management, enhance therapy effectiveness, and improve patient comfort through adaptive real-time stimulation. A closed-loop rechargeable spinal cord stimulator is an implantable device that automatically adjusts electrical nerve stimulation in real time to maintain consistent pain relief and operates with a rechargeable battery for long-term use. For instance, in April 2024, Medtronic plc, an Ireland-based medical device company, launched Inceptiv, a closed-loop rechargeable spinal cord stimulator (SCS). The product received approval from the Food and Drug Administration (FDA) for the treatment of chronic pain in the trunk and/or limbs, including unilateral or bilateral pain. The device detects evoked compound action potentials (ECAPs) or similar biological signals along the spinal cord and uses them as a real-time biomarker of dorsal column activation.

Major companies operating in the implantable neuromodulation and spinal cord stimulation devices market are Medtronic plc; Abbott Laboratories; Boston Scientific Corporation; LivaNova PLC; Nevro Corp.; NeuroPace Inc.; Saluda Medical Pty Ltd.; Mainstay Medical Holdings plc; Integer Holdings Corporation; Biotronik SE & Co. KG; Cirtec Medical Corporation; Neuspera Medical Inc.; ONWARD Medical; Neuros Medical; Synchron; Synapse Biomedical Inc.; CorTec GmbH; Aleva Neurotherapeutics SA; Gimer Medical Co. Ltd.; SceneRay Corporation; Nexstim Plc.

North America was the largest region in the implantable neuromodulation and spinal cord stimulation devices market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the implantable neuromodulation and spinal cord stimulation devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the implantable neuromodulation and spinal cord stimulation devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The implantable neuromodulation and spinal cord stimulation devices market consists of sales of dorsal root ganglion stimulation devices, gastric electrical stimulation devices, and hypoglossal nerve stimulation devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The implantable neuromodulation and spinal cord stimulation devices market research report is one of a series of new reports that provides implantable neuromodulation and spinal cord stimulation devices market statistics, including implantable neuromodulation and spinal cord stimulation devices industry global market size, regional shares, competitors with a implantable neuromodulation and spinal cord stimulation devices market share, detailed implantable neuromodulation and spinal cord stimulation devices market segments, market trends and opportunities, and any further data you may need to thrive in the implantable neuromodulation and spinal cord stimulation devices industry. This implantable neuromodulation and spinal cord stimulation devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

This product will be delivered within 1-3 business days.